BioCentury
ARTICLE | Clinical News

OBE001: Phase II started

July 13, 2015 7:00 AM UTC

ObsEva began the double-blind, placebo-controlled, European Phase II TERM trial to evaluate oral OBE001 once daily for up to 7 days in 100 patients. ObsEva has exclusive, worldwide rights to OBE001 fr...